Results 41 to 50 of about 1,058 (155)

DETERMINATION OF THE IMPACT OF BISOPROLOL AND СARVEDILOL ON REGULATORY-ADAPTIVE STATUS OF PATIENTS WITH CHRONIC HEART FAILURE AND PRESERVED LEFT VENTRICULAR FRACTION

open access: yesЕвразийский Кардиологический Журнал, 2020
Objective. To determine the effect of bisoprolol or carvedilol therapy on the regulatory-adaptive status (RAS) of patients with chronic heart failure (CHF) and preserved ejection fraction (pEF) of the left ventricle (LV) the background of hypertensive ...
V. G. Tregubov   +3 more
doaj   +1 more source

Quinapril: Overview of preclinical data [PDF]

open access: yesClinical Cardiology, 2009
Quinapril hydrochloride, a new, orally active, nonpeptide, nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor, has been studied extensively in a variety of in vitro and in vivo animal models. Quinapril inhibits the contractile and pressor effects of angiotensin I in rabbit aorta and in rats, respectively, and lowers blood pressure in both high-
H R, Kaplan, D G, Taylor, S C, Olson
openaire   +2 more sources

The Management of Parkinson's Disease Before, during and after Pregnancy—an MDS Scientific Issues Committee Review

open access: yesMovement Disorders Clinical Practice, Volume 13, Issue 1, Page 44-59, January 2026.
Abstract Background Pregnancy after a Parkinson's diagnosis presents complex challenges. Due to the paucity of literature, there is no evidence‐based guidelines and protocols for preconception care, management of pregnancy, childbirth and the postpartum period in women with early‐onset Parkinson's disease (PD).
Alexander C. Lehn   +18 more
wiley   +1 more source

Determinants of renal drug elimination: Effect of renal metabolism on the renal disposition of quinapril and quinaprilat.

open access: yes, 1993
Quinapril, the esterified prodrug of the active metabolite quinaprilat, is a nonsulfhydryl ACE inhibitor used in hypertension therapy and is under investigation for congestive heart failure therapy.
Kugler, Alan Roger
core   +5 more sources

Drug‐Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort

open access: yesFundamental &Clinical Pharmacology, Volume 40, Issue 6, November 2026.
ABSTRACT Background Angiotensin receptor blockers (ARBs) have demonstrated neuroprotective effects in preclinical models of Parkinson's disease (PD), but individual ARBs differ in pharmacological properties that may influence their neuroprotective potential. Objectives Using large‐scale hospital electronic health records of the University of California
Kyle Tran   +8 more
wiley   +1 more source

Estimation of angiotensin-converting enzyme inhibitors protein binding degree using chromatographic hydrophobicity data [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo, 2015
Introduction. Angiotensin-converting enzyme (ACE) inhibitors represent a significant group of drugs primarily used in the treatment of hypertension and congestive heart failure. Objective.
Trbojević-Stanković Jasna   +2 more
doaj   +1 more source

Molecular basis of domain‐specific angiotensin I‐converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat

open access: yesThe FEBS Journal, Volume 293, Issue 2, Page 475-491, January 2026.
Inhibition of angiotensin I‐converting enzyme is an effective strategy for the treatment of hypertension. However, the clinically available ACE inhibitors cause side effects due to nonselective inhibition of the two catalytic domains of ACE (nACE and cACE).
Kyle S. Gregory   +3 more
wiley   +1 more source

Spontaneous Remission of Late Relapsing Membranous Nephropathy After Previous Immunosuppressant‐Induced Remission: Case Report

open access: yesCase Reports in Nephrology, Volume 2026, Issue 1, 2026.
This is the first detailed report of spontaneous remission of late relapsing membranous nephropathy (MN) after previous immunosuppressant‐induced remission. In March 2004, a 52‐year‐old Hispanic male presented with severe nephrotic syndrome with proteinuria of 13 g/24 h. The workup for infectious and autoimmune diseases was unrevealing.
Yangming Cao, Poorani Gurumallesh Prabu
wiley   +1 more source

Identification of Neuroinflammation‐Related Diagnostic Biomarkers in Metabolic Dysfunction–Associated Steatohepatitis: An Integrated Bioinformatics and Machine Learning Approach

open access: yesGastroenterology Research and Practice, Volume 2026, Issue 1, 2026.
Background Metabolic dysfunction–associated steatohepatitis (MASH) is a liver disease that progresses and may be connected to neuroinflammation, though the specific molecular mechanisms are not yet understood. The objective of this research was to explore candidate diagnostic biomarkers related to neuroinflammation‐associated gene programs for MASH ...
Yuliang Jia   +4 more
wiley   +1 more source

Utilization and Dose Optimization of Angiotensin‐Converting Enzyme Inhibitors in Heart Failure Patients With Reduced Ejection Fraction: A Cross Sectional Study on Implications for Guideline‐Targeted Therapy

open access: yesHealth Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims Angiotensin‐converting enzyme inhibitors (ACEIs) are well established in reducing morbidity and mortality among patients with chronic heart failure (CHF). Evidence has consistently supported the use of high‐dose ACEI therapy, which is recommended to optimize clinical outcomes and enhance patients' quality of life ...
Martin Kampamba   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy